Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-A11KRASG12V-TCR in Metastatic Solid Tumors with KRAS G12V Mutations
NCT06043713Phase 1Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FH-A11KRASG12V-TCR in non-small cell lung cancer (NSCLC), pancreatic cancer (PC), colon cancer and 1 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of adverse events at 1 year, Dose-limiting toxicity rates at 28 days and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
FH-A11KRASG12V-TCR
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic cancer (PC)colon cancersolid tumor
Beyond the preview
Go deeper on NCT06043713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043713.